A Randomized, Placebo-Controlled, Double-Blind, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of the Gamma-Secretase Modulator BMS-932481 in Healthy Young and Elderly Individuals

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of the Gamma-Secretase Modulator BMS-932481 in Healthy Young and Elderly Individuals

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2013

At a glance

  • Drugs BMS 932481 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 14 Aug 2013 New trial record
    • 14 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top